- Home
- SSP vs IMMP Comparison
SSP vs IMMP Comparison
Compare SSP & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSP
- IMMP
- Stock Information
- Founded
- SSP 1878
- IMMP 1987
- Country
- SSP United States
- IMMP Australia
- Employees
- SSP N/A
- IMMP N/A
- Industry
- SSP Broadcasting
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- SSP Industrials
- IMMP Health Care
- Exchange
- SSP Nasdaq
- IMMP Nasdaq
- Market Cap
- SSP 264.1M
- IMMP 251.8M
- IPO Year
- SSP 1988
- IMMP N/A
- Fundamental
- Price
- SSP $2.91
- IMMP $1.64
- Analyst Decision
- SSP Buy
- IMMP Buy
- Analyst Count
- SSP 2
- IMMP 1
- Target Price
- SSP $5.50
- IMMP $7.00
- AVG Volume (30 Days)
- SSP 593.0K
- IMMP 86.7K
- Earning Date
- SSP 11-03-2025
- IMMP 10-21-2025
- Dividend Yield
- SSP N/A
- IMMP N/A
- EPS Growth
- SSP N/A
- IMMP N/A
- EPS
- SSP 0.48
- IMMP N/A
- Revenue
- SSP $2,439,152,000.00
- IMMP $3,306,742.00
- Revenue This Year
- SSP N/A
- IMMP N/A
- Revenue Next Year
- SSP $10.24
- IMMP $725.37
- P/E Ratio
- SSP $6.14
- IMMP N/A
- Revenue Growth
- SSP 5.25
- IMMP 31.28
- 52 Week Low
- SSP $1.36
- IMMP $1.32
- 52 Week High
- SSP $4.17
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- SSP 46.80
- IMMP 46.06
- Support Level
- SSP $2.75
- IMMP $1.60
- Resistance Level
- SSP $3.13
- IMMP $1.68
- Average True Range (ATR)
- SSP 0.16
- IMMP 0.07
- MACD
- SSP -0.01
- IMMP -0.00
- Stochastic Oscillator
- SSP 28.57
- IMMP 28.12
About SSP E.W. Scripps Company (The)
The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.